Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LUNG Pulmonx Corp
- Stocks
- Healthcare
- NASDAQ: LUNG
Price (delayed)
$3.08
Market cap
$123.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.44
Enterprise value
$106.13M
Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment
Highlights
The revenue has grown by 20% YoY and by 4.4% from the previous quarter
Pulmonx's gross profit has increased by 18% YoY and by 3.7% from the previous quarter
Pulmonx's debt has increased by 40% YoY
The quick ratio is down by 31% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of LUNG
Market
Valuations
Earnings
Shares outstanding
40.26M
Market cap
$123.99M
Enterprise value
$106.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
1.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.21
Revenue
$87.47M
Gross profit
$64.27M
Operating income
-$57.73M
Net income
-$57.09M
EBIT
-$53.24M
EBITDA
-$50.39M
Free cash flow
-$34.26M
Per share
Balance sheet
Liquidity
EPS
-$1.44
EPS diluted
-$1.44
Free cash flow per share
-$0.86
Book value per share
$1.95
Revenue per share
$2.19
TBVPS
$3.71
Total assets
$150.74M
Total liabilities
$73.07M
Debt
$56.95M
Equity
$77.67M
Working capital
$98.99M
Debt to equity
0.73
Current ratio
4.97
Quick ratio
4.13
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
-57.6%
Gross margin
73.5%
Net margin
-65.3%
Operating margin
-66%
Return on assets
-34.9%
Return on equity
-63.7%
Return on invested capital
-41.6%
Return on capital employed
-42.3%
Return on sales
-60.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LUNG stock price
How has the Pulmonx stock price performed over time
Intraday
-3.14%
1 week
4.05%
1 month
-18.3%
1 year
-55.81%
YTD
-54.64%
QTD
-54.23%
Financial performance
How have Pulmonx's revenue and profit performed over time
Revenue
$87.47M
Gross profit
$64.27M
Operating income
-$57.73M
Net income
-$57.09M
Gross margin
73.5%
Net margin
-65.3%
The revenue has grown by 20% YoY and by 4.4% from the previous quarter
Pulmonx's operating margin has increased by 20% YoY and by 4.2% from the previous quarter
Pulmonx's net margin has increased by 19% YoY and by 3% QoQ
Pulmonx's gross profit has increased by 18% YoY and by 3.7% from the previous quarter
Price vs fundamentals
How does LUNG's price correlate with its fundamentals
Growth
What is Pulmonx's growth rate over time
Valuation
What is Pulmonx stock price valuation
P/E
N/A
P/B
1.58
P/S
1.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.21
Pulmonx's EPS has increased by 6% YoY
The P/B is 66% lower than the 5-year quarterly average of 4.6 and 49% lower than the last 4 quarters average of 3.1
The company's equity fell by 30% YoY and by 9% QoQ
The price to sales (P/S) is 90% less than the 5-year quarterly average of 14.2 and 59% less than the last 4 quarters average of 3.4
The revenue has grown by 20% YoY and by 4.4% from the previous quarter
Efficiency
How efficient is Pulmonx business performance
The company's return on equity fell by 32% YoY and by 11% QoQ
Pulmonx's ROS has increased by 18% YoY and by 2.6% from the previous quarter
LUNG's return on invested capital is up by 16% year-on-year but it is down by 2.7% since the previous quarter
The ROA fell by 7% YoY and by 3.3% QoQ
Dividends
What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LUNG.
Financial health
How did Pulmonx financials performed over time
Pulmonx's total assets is 106% more than its total liabilities
Pulmonx's total liabilities has increased by 35% YoY but it has decreased by 5% from the previous quarter
The quick ratio is down by 31% year-on-year and by 12% since the previous quarter
Pulmonx's debt is 27% lower than its equity
The debt to equity has surged by 97% year-on-year and by 11% since the previous quarter
Pulmonx's debt has increased by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.